Polen Capital Management LLC Has $7.79 Million Stock Position in GeneDx Holdings Corp. $WGS

Polen Capital Management LLC reduced its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 12.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,861 shares of the company’s stock after selling 8,308 shares during the period. Polen Capital Management LLC owned 0.21% of GeneDx worth $7,786,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. ARK Investment Management LLC lifted its stake in shares of GeneDx by 35.3% in the fourth quarter. ARK Investment Management LLC now owns 604,561 shares of the company’s stock worth $78,629,000 after buying an additional 157,582 shares during the last quarter. Empowered Funds LLC bought a new stake in GeneDx during the fourth quarter valued at about $73,000. Renaissance Group LLC acquired a new stake in shares of GeneDx in the fourth quarter valued at about $7,167,000. Deutsche Bank AG increased its stake in shares of GeneDx by 3.0% in the fourth quarter. Deutsche Bank AG now owns 16,507 shares of the company’s stock worth $2,147,000 after purchasing an additional 482 shares during the period. Finally, Amova Asset Management Americas Inc. lifted its position in shares of GeneDx by 30.6% during the 4th quarter. Amova Asset Management Americas Inc. now owns 381,725 shares of the company’s stock worth $49,647,000 after purchasing an additional 89,470 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

Key Stories Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Hedge fund interest may be supportive for sentiment, as reports say Eli Casdin is loading up on GeneDx shares. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
• Neutral Sentiment: Several law firms reiterated that a class action has been filed against GeneDx and that investors have until August 3, 2026 to seek lead-plaintiff status. Investor Alert: Pomerantz Law Firm Reminds Investors…
• Neutral Sentiment: Additional notices from Rosen, Faruqi & Faruqi, Schall, Robbins LLP, and others kept the securities-fraud case in the spotlight, reinforcing legal overhang rather than adding new operational news. ROSEN, TOP RANKED INVESTOR COUNSEL…
• Negative Sentiment: GeneDx CEO Katherine Stueland and CFO Kevin Feeley both sold shares on June 9, though the company said the sales were to cover tax withholding tied to equity vesting. CEO Form 4 Filing

Insider Buying and Selling

In other news, Director Keith A. Meister bought 46,273 shares of GeneDx stock in a transaction dated Friday, May 15th. The shares were bought at an average price of $38.91 per share, for a total transaction of $1,800,482.43. Following the purchase, the director owned 4,784,570 shares of the company’s stock, valued at approximately $186,167,618.70. This trade represents a 0.98% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Casdin Capital, Llc bought 50,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were purchased at an average price of $52.86 per share, with a total value of $2,643,000.00. Following the transaction, the director directly owned 3,707,164 shares in the company, valued at $195,960,689.04. This represents a 1.37% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders acquired 2,256,420 shares of company stock worth $93,144,340 and sold 77,287 shares worth $5,153,215. 29.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

WGS has been the topic of several recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 price target (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Guggenheim dropped their target price on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. BTIG Research reduced their price target on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Weiss Ratings lowered shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, Zacks Research lowered shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, GeneDx presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

GeneDx Trading Up 12.3%

Shares of GeneDx stock opened at $60.99 on Friday. GeneDx Holdings Corp. has a 52-week low of $32.21 and a 52-week high of $170.87. The firm has a market capitalization of $1.81 billion, a PE ratio of -22.76 and a beta of 1.96. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The company’s fifty day moving average price is $55.07 and its two-hundred day moving average price is $90.41.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The business had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same quarter in the prior year, the business earned ($0.23) EPS. On average, analysts expect that GeneDx Holdings Corp. will post -1 EPS for the current year.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.